Current and future therapies for advanced pancreatic cancer
R Gupta, I Amanam, V Chung - Journal of surgical oncology, 2017 - Wiley Online Library
Pancreatic cancer remains a deadly disease with a 5‐year survival rate of only 8%. Even
after surgical resection, most patients have recurrence of their cancer. Over the last 10 years …
after surgical resection, most patients have recurrence of their cancer. Over the last 10 years …
Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis
AA Mokdad, RM Minter, H Zhu… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To compare overall survival between patients who received neoadjuvant therapy
(NAT) followed by resection and those who received upfront resection (UR)—as well as a …
(NAT) followed by resection and those who received upfront resection (UR)—as well as a …
Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes
Simple Summary Pancreatic adenocarcinoma is the fourth leading cause of cancer-related
death in industrialized countries. In locally advanced and borderline resectable pancreatic …
death in industrialized countries. In locally advanced and borderline resectable pancreatic …
Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology
HJ Burstein, L Krilov, JB Aragon-Ching… - Journal of Clinical …, 2017 - ascopubs.org
A MESSAGE FROM ASCO'S PRESIDENT I am pleased to present Clinical Cancer
Advances 2017, which highlights the most promising advances in patient-oriented cancer …
Advances 2017, which highlights the most promising advances in patient-oriented cancer …
Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1A and cytokeratin-81 correlates with outcome and treatment response
A Muckenhuber, AK Berger, AM Schlitter, K Steiger… - Clinical Cancer …, 2018 - AACR
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with a dismal prognosis
and poor therapeutic response to current chemotherapy regimens in unselected patient …
and poor therapeutic response to current chemotherapy regimens in unselected patient …
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer-the NEONAX trial (AIO-PAK-0313), a prospective …
TJ Ettrich, AW Berger, L Perkhofer, S Daum, A König… - BMC cancer, 2018 - Springer
Background Even clearly resectable pancreatic cancer still has an unfavorable prognosis.
Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus …
Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus …
[HTML][HTML] δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis
K Husain, BA Centeno, D Coppola, J Trevino… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The growth, metastasis, and chemotherapy resistance of pancreatic ductal adenocarcinoma
(PDAC) is characterized by the activation and growth of tumor-initiating cells in distant …
(PDAC) is characterized by the activation and growth of tumor-initiating cells in distant …
The match between molecular subtypes, histology and microenvironment of pancreatic cancer and its relevance for chemoresistance
J Martinez-Useros, M Martin-Galan, J Garcia-Foncillas - Cancers, 2021 - mdpi.com
Simple Summary Based on the four molecular subtypes of pancreatic cancer described by
Bailey et al. 2016, in the present article we match the molecular, histology and …
Bailey et al. 2016, in the present article we match the molecular, histology and …
Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective
VJ Picozzi, SY Oh, A Edwards, MT Mandelson… - Annals of surgical …, 2017 - Springer
Background Successful surgical resection combined with effective perioperative therapy is
essential for maximizing long-term survival for pancreatic adenocarcinoma. Patients and …
essential for maximizing long-term survival for pancreatic adenocarcinoma. Patients and …
Pancreatic cancer:“a riddle wrapped in a mystery inside an enigma”
Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult-to-treat cancers. With
an increasing incidence and inability to make major progress, it represents the very …
an increasing incidence and inability to make major progress, it represents the very …